Strategy of membrane protection in pharmacotherapy of vascular cognitive impairment

Authors

  • S.G. Burchinsky State Institution “D.F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2224-0713.16.8.2020.221959

Keywords:

cognitive dysfunction, mild cognitive impairment syndrome, cerebrovascular pathology, citicoline

Abstract

The article considers modern views on the problem of vascular cognitive dysfunction, in particular, on the nature and options of treatment of mild cognitive impairment syndrome as one of the most common forms of cognitive decline in the elderly and senile patients. From this point of view, the requirements for the selection of the optimal pharmacological tool for pharmacotherapy and pharmacoprophylaxis of this syndrome, especially the strategy of membrane protection, are analyzed. Particular attention is paid to the mechanisms of action and features of clinical use of Lira (citicoline) — a drug with unique clinical and pharmacological properties that allow implementing a strategy of pathogenetically sound neuro- and geroprotective pharmacotherapy in cerebrovascular disorders. Mechanisms of action, clinical efficacy of Lira (citicoline), safety characteristics and recommendations for practical use of the drug are considered in detail.

References

Бачинская Н.Ю. Синдром мягкого когнитивного снижения у лиц старшего возраста. Журн. АМН України. 2004. Т. 10. № 3. С. 555-562.

Бачинська Н.Ю., Рожелюк І.Ф., Холін В.О., Демченко О.В., Шулькевич А.А. Застосування екстракту гінкго білоба у хворих похилого віку із синдромом помірних когнітивних порушень. Журн. неврол. ім. Н.Б. Маньковського. 2015. № 2. С. 13-20.

Бурчинський С.Г. Сучасні аспекти фармакопрофілактики. 1. Ноотропні засоби. Вісник фармакол., фарм. 2003. № 5. С. 18-21.

Бурчинский С.Г. Нейропротекция как комплексная фармакотерапевтическая и фармакопрофилактическая стратегия. Therapia. 2008. № 2. С. 53-56.

Бурчинський С.Г. Вік-залежна патологія центральної нервової системи: від фармакології до фармакотерапії. Рац. фармакотер. 2010. № 2. С. 30-33.

Бурчинський С.Г. Комбінована нейропротекція при хронічній ішемії головного мозку: цілі, завдання, інструменти. Міжнар. неврол. журн. 2020. № 3. С. 23-26.

Дамулин И.В. Использование ривастигмина при деменциях: от симптоматического эффекта к нейропротекции. Журн. неврол. и психиат. 2010. Т. 110. № 9. С. 76-82.

Кадыков А.С., Шахпаронова Н.Б., Гришина Д.А. Роль препарата Билобил в лечении больных с сосудистыми заболеваниями головного мозга. Рус. мед. журн. 2008. Т. 16. № 26. С. 1736-1738.

Колыхалов И.В. Современные подходы к оптимизации терапии болезни Альцгеймера. Журн. неврол. и психиат. 2016. Т. 116. № 6. С. 87-92.

Маньковский Н.Б., Бачинская Н.Ю. Синдром умеренных когнитивных нарушений и старение. Журн. неврол. 2014. Т. 2. № 1. С. 5-11.

Мищенко Т.С. Деменция — это не нозологическая форма, а синдром. НейроNews. 2009. № 2/1. С. 6-9.

Мищенко Т.С., Мищенко В.Н. Сосудистая деменция. НейроNews. 2011. № 2/1. С. 32-34.

Преображенская И.С., Яхно Н.Н. Возрастная когнитивная дисфункция: диагностика и лечение. Журн. невропатол. и психиат. 2006. Т. 106. № 11. С. 33-38.

Суслина З.А., Максимова М.Ю., Федорова Т.Н. Оксидантный стресс и основные направления нейропротекции при нарушениях мозгового кровообращения. Неврол. журн. 2007. № 4. С. 24-28.

Табеева Г.Р. Умеренные когнитивные расстройства: что дальше? Журн. неврол. и психиат. 2019. Т. 119. № 10. С. 103-110.

Alvarez-Sabin J., Roman G.C. Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke. 2011. V. 42. P. S40-S43.

Anand A., Patience A.A., Sharma N. et al. The present and future of pharmacotherapy of Alzheimer’s disease: a comprehensive review. Eur. J. Pharmacol. 2017. V. 815. P. 364-375.

Bernadetti O., Luisao T. Cognitive impairments in geriatric practice. Handb. Clin. Neurogeriatr. 2018. N.Y.: Ettenboro Press. P. 146-169.

Cheng Y.W., Chen T.F., Chiu M.J. From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution. Neuropsychiat. Dis. Treat. 2017. V. 13. P. 491-498.

Claiton A. Citicoline: neurochemical basis and clinical findings. Neurochem. Res. Rev. 2018. V. 11. P. 110-129.

Controneo A.M., Castagna A., Punignano S. et al. Effectiveness and safety of citicoline in mild cognitive impairment: the IDEALE study. Clin. Invest. Aging. 2013. V. 8. P. 131-137.

Corey-Bloom J. The ABC of Alzheimer’s disease: cognitive changes and their management in Alzheimer’s disease and related dementias. Int. Psychogeriat. 2002. V. 14. Suppl. 1. P. 51-75.

Davis H.S., Rockwood K. Conceptualization of mild cognitive impairment: a review. Int. J. Geriatr. Psychiat. 2004. V. 19. P. 313-319.

Ellergast J.P. Gamma-aminobutyric acid — mediated neurophysiological effects in the central nervous system. Brain neurophysio­logy. Chicago: Illinois Univ. Press, 2000. P. 497-530.

Farlow M.R., Cummings J.L., Effective pharmacological ma-nagement of Alzheimer’s disease. Am. J. Med. 2007. V. 120. P. 388-397.

Farooqui A.A., Horrocks L.A., Farooqui T. Glycerophospholipids in brain: their metabolism, incorporation to membranes, functions, and involvement in neurological disorders. Chem. Phys. Lipids. 2000. V. 106. P. 1-29.

Hock C. Biochemical aspects of dementia. Dial. Clin. Neurosci. 2003. V. 5. P. 27-34.

Hurtado O., Moro M.A., Cardenas A. et al. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiol. Dis. 2005. V. 18. P. 336-345.

Mendez M.F., Cummings J.L. Dementia. Philadelphia: Butterworth Heinemann, 2003. 654 p.

Petersen R.C., Caracciolo B., Brayne C. et al. Mild cognitive impairment: a concept in evolution. J. Intern. Med. 2014. V. 275. P. 214-228.

Rose T.J., Cummings P., Jones T.A. Acetylcholine. Brain Neurotransmission: from physiology — to clinics. London: Ettenboro Press, 2006. P. 165-230.

Runge D.G. Use and misuse of different pharmacological agents in mild cognitive impairments. Arch. Clin. Neurol & Neuropharmacol. 2017. V. 6. P. 216-230.

Saver J.L. Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair. Rev. Neurol. Dis. 2008. V. 5. P. 167-177.

Schneider J.A., Arvanitakis Z., Bang W. et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007. V. 69. P. 2197-2204.

Secades J.J. CDP-choline: update and review of its pharmacology and clinical use. Meth. Find. Exp. Clin. Pharmacol. 2002. V. 24. Suppl. B. P. 1-53.

Secades J.J., Lorenzo J.L. Citicoline: pharmacological and clinical review. 2006 update. Meth. Find. Exp. Clin. Pharmacol. 2006. V. 28. Suppl. B. P. 1-56.

Shanks M., Kivipelto M., Bullock R. et al. Cholinesterase inhibition: is their evidence for disease-modifying effects? Curr. Med. Res. Opin. 2009. V. 25. P. 2439-2446.

Downloads

Published

2020-11-01

Issue

Vol. 16 No. 8 (2020)

Section

To practicing Neurologist

License

Copyright (c) 2021 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our edition uses the copyright terms of Creative Commons for open access journals.

Authors, who are published in this journal, agree with the following terms:

  1. The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
  2. Directing  the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
  3. The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
  4. The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
  5. The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
  6. The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
  7. The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.